Eton Pharmaceuticals (ETON) Receivables (2019 - 2025)

Eton Pharmaceuticals (ETON) has 7 years of Receivables data on file, last reported at $11.8 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables rose 119.31% year-over-year to $11.8 million; the trailing twelve-month figure through Dec 2025 stood at $11.8 million (up 119.31% YoY), and the FY2025 full-year result was $11.8 million, up 119.31% from the prior year.
• Receivables fell to $11.8 million in Q4 2025, from $13.1 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $14.5 million in Q2 2025 to a low of $300000.0 in Q1 2021.
• A 5-year average of $4.4 million and a median of $3.5 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 10316.67% in 2021 and tumbled 62.96% in 2022, its largest moves.
• Tracing ETON's Receivables over 5 years: stood at $5.0 million in 2021, then slumped by 62.96% to $1.9 million in 2022, then jumped by 84.18% to $3.4 million in 2023, then soared by 57.17% to $5.4 million in 2024, then surged by 119.31% to $11.8 million in 2025.
• Business Quant data shows ETON's Receivables at $11.8 million in Q4 2025, $13.1 million in Q3 2025, and $14.5 million in Q2 2025.